P8Z Stock Analysis: Bumitama Agri | SG

Farm Products | SG, Singapore | Market Cap: 3.607m SGD | 12M Return: 101.7% | SG2E67980267 | Charts, Fundamentals & Technical Analysis

Crude Palm Oil, Palm Kernel, Edible Oils, Plantations
Total Rating 72
Safety 82
Buy Signal 1.13
Farm Products
Industry Rotation: -6.2
Market Cap: 2.82B
Avg Turnover: 6.16M
Risk 3d forecast
Volatility75.1%
VaR 5th Pctl10.7%
VaR vs Median-10.2%
Reward TTM
Sharpe Ratio1.58
Rel. Str. IBD94.6
Rel. Str. Peer Group95
Character TTM
Beta-0.018
Beta Downside-0.295
Hurst Exponent0.441
Drawdowns 3y
Max DD30.72%
CAGR/Max DD2.32
CAGR/Mean DD10.89

Warnings

No concerns identified

Tailwinds

Rs Leader
Idiosyncratic Leader
Confidence

Seasonality 11.7 years of data

Jan +0.0% 7
Feb -1.7% 15
Mar +1.6% 21
Apr +5.1% 37
May -2.7% 25
Jun -1.3% 42
Jul -0.5% 7
Aug +2.1% 40
Sep +0.5% 2
Oct +1.1% 17
Nov +2.7% 56
Dec -1.6% 40

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: P8Z Bumitama Agri

Bumitama Agri Ltd. is an Indonesia-based investment holding company engaged in the production and trading of crude palm oil (CPO) and palm kernel (PK). The company operates an integrated value chain spanning oil palm plantations, palm oil mills, and a fertilizer blending plant. It cultivates, harvests, and processes fruit from oil palm trees to produce and sell CPO and PK, while also providing business, management, and consultancy services, and trading in edible oils and related products. Founded in 1996, Bumitama is headquartered in Jakarta Selatan, Indonesia.

Indonesia is the worlds largest producer of crude palm oil, and the industry is a major contributor to the countrys export economy. Vertically integrated producers like Bumitama control the supply chain from plantation cultivation through milling and downstream trading, which is a common business model aimed at capturing margin across multiple stages and managing input costs such as fertilizer internally.

Headlines to Watch Out For
  • CPO prices rise on tight global edible oil supply
  • Indonesia biodiesel mandate expansion lifts domestic demand
  • EU deforestation rules pressure export volumes and pricing
Piotroski VR-10 (Strict) 8.5
Net Income: 2803b TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA 4.94 > 1.0
NWC/Revenue: 16.60% < 20% (prev 24.14%; Δ -7.53% < -1%)
CFO/TA 0.20 > 3% & CFO 4672b > Net Income 2803b
Net Debt/EBITDA: error (cannot be calculated)
Current Ratio: 1.90 > 1.5 & < 3
Outstanding Shares: last quarter (1.73b) vs 12m ago 0.0% < -2%
Gross Margin: 27.96% > 18% (prev 26.04%; Δ 1.92% > 0.5%)
Asset Turnover: 88.32% > 50% (prev 77.68%; Δ 10.63% > 0%)
Interest Coverage Ratio: 18.50 > 6 (EBIT TTM 3093b / Interest Expense TTM 167b)
Altman Z'' 6.67
A: 0.14 (Total Current Assets 7008b - Total Current Liabilities 3695b) / Total Assets 23643b
B: 0.60 (Retained Earnings 14150b / Total Assets 23643b)
C: 0.14 (EBIT TTM 3093b / Avg Total Assets 22591b)
D: 2.75 (Book Value of Equity 15540b / Total Liabilities 5657b)
Altman-Z'' = 6.67 = AAA
Beneish M -3.65
DSRI: 0.21 (Receivables 191b/776b, Revenue 19951b/16732b)
GMI: 0.93 (GM 26.04% / 27.96%)
AQI: 0.93 (AQ_t 0.10 / AQ_t-1 0.10)
SGI: 1.19 (Revenue 19951b / 16732b)
TATA: -0.08 (NI 2803b - CFO 4672b) / TA 23643b)
Beneish M = -3.65 (Cap -4..+1) = AAA
What is the price of P8Z shares?

As of September 27, 2026, the stock is trading at SGD 2.16 with a total of 1,448,000 shares traded. Over the past week, the price has changed by -13.25%, over one month by +5.88%, over three months by +34.28% and over the past year by +101.70%.

Current recommended Stop Loss: 1.90 (which is 12% or 2.2 ATR below the current price).

Is P8Z a buy, sell or hold?

Bumitama Agri has no consensus analysts rating.

Bumitama Agri (P8Z) - Fundamental Data Overview as of 25 September 2026
Market Cap USD = 2.82b (3.61b SGD * 0.7824 SGD.USD)
Market Cap IDR = 50459b (3.61b SGD * 13989.131835938 SGD.IDR)
P/E Trailing = 15.5714
P/E Forward = 12.87
P/S = 2.2873
P/B = 3.2823
P/EG = 0.825
Revenue TTM = 19951b IDR
EBIT TTM = 3093b IDR
EBITDA TTM = 4083b IDR
Long Term Debt = 1586b IDR (from longTermDebt, last quarter)
Short Term Debt = 1757b IDR (from shortLongTermDebt, last quarter)
 Debt = unknown
 Net Debt = unknown
 Enterprise Value = 47163b IDR (50459b + (null Debt) - CCE 3296b)
Interest Coverage Ratio = 18.50 (Ebit TTM 3093b / Interest Expense TTM 167b)
EV/FCF = 15.09x (Enterprise Value 47163b / FCF TTM 3126b)
FCF Yield = 6.63% (FCF TTM 3126b / Enterprise Value 47163b)
FCF Margin = 15.67% (FCF TTM 3126b / Revenue TTM 19951b)
Net Margin = 14.05% (Net Income TTM 2803b / Revenue TTM 19951b)
Gross Margin = 27.96% ((Revenue TTM 19951b - Cost of Revenue TTM 14373b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.99 (Enterprise Value 47163b / Total Assets 23643b)
 Interest Expense / Debt = unknown (Interest Expense 167b / Debt none)
 Taxrate = 27.79% (1295b / 4660b)
NOPAT = 2233b (EBIT 3093b * (1 - 27.79%))
Current Ratio = 1.90 (Total Current Assets 7008b / Total Current Liabilities 3695b)
 Debt / Equity = unknown (Debt none)
 Debt / EBITDA = unknown (Net Debt none / EBITDA 4083b)
 Debt / FCF = unknown (Net Debt none / FCF TTM 3126b)
 Total Stockholder Equity = 14771b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.41% (Net Income 2803b / Total Assets 23643b)
RoE = 18.97% (Net Income TTM 2803b / Total Stockholder Equity 14771b)
RoCE = 18.91% (EBIT 3093b / Capital Employed (Equity 14771b + L.T.Debt 1586b))
RoIC = 11.78% (NOPAT 2233b / Invested Capital 18951b)
WACC = 5.92% (E(50459b)/V(50459b) * Re(5.92%) + (debt-free company))
Discount Rate = 5.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -52.22 | Cagr: -0.09%
[DCF] Terminal Value 77.97% ; FCFF base≈2589b ; Y1≈2968b ; Y5≈4368b
[DCF] Fair Price = 37.9k (EV 65725b - Net Debt 0.0 = Equity 65725b / Shares 1.73b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
Revenue Correlation: 97.75 | Revenue CAGR: 13.66% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2203.00 | Chg30d=+1.24% | Revisions=+17% | GrowthEPS=+36.3% | GrowthRev=+21.1%
EPS next Year (2027-12-31): EPS=2242.02 | Chg30d=+1.25% | Revisions=+17% | GrowthEPS=+1.8% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +22% (up=4, down=2)